SRARP is co-expressed with the estrogen receptor (ER) and androgen receptor (AR) in breast cancer.[8][9] In the ER-positive breast cancer cells, SRARP is involved in the transcriptional activities of ER and has shown an interaction with ER using the transient transfection of cells with SRARP and ER constructs.[10][11] In addition, in AR+ breast cancer cells, SRARP interacts with the endogenous AR protein and acts as a transcriptional corepressor of AR.[9] Furthermore, the activation of either AR or ER negatively regulates SRARP expression in breast cancer cells.[9][10]
SRARP and HSPB7[12] are gene pairs that are positioned 5 kb apart on chromosome 1p36.13.[13] It is notable that the loss of chromosome 1p36.1 is common in malignancies, occurring in 34% of tumors[14][15] SRARP and HSPB7 are broadly inactivated in malignancies by epigenetic silencing, copy-number loss, and less frequently by somatic mutations.[13] In addition, overexpression of SRARP or HSPB7 leads to tumor suppressor effects in cancer cell lines.[13] Another similar molecular feature between SRARP and HSPB7 is the fact that both of these proteins interact with the 14-3-3 protein.[9][13] Furthermore, SRARP is a potential cancer biomarker and SRARP inactivation predicts poor clinical outcome in malignancies and adjacent normal tissues using the analysis of large genomic datasets[13]
^ abLuo A, Su D, Zhang X, Qi L, Fu L, Dong JT (September 2016). "Estrogen-estrogen receptor signaling suppresses the transcription of ERRF in breast cancer cells". Journal of Genetics and Genomics = Yi Chuan Xue Bao. 43 (9): 565–567. doi:10.1016/j.jgg.2016.06.003. PMID27599921.
^Luo A, Zhang X (May 2016). "ERRF is essential for Estrogen-Estrogen Receptor alpha signaling pathway in ER positive breast cancer cells". Biochemical and Biophysical Research Communications. 474 (2): 400–405. doi:10.1016/j.bbrc.2016.04.132. PMID27125460.
